| Literature DB >> 25280498 |
Asrat Agalu Abejew1, Ayele A Denboba, Alemayehu Gashaw Mekonnen.
Abstract
BACKGROUND: Different studies have indicated that urinary tract infections frequently occur in both community and hospital environments and are of the most common bacterial infections in humans. the outcomes of urinary tract infections are increased hospitalization, increased direct patient costs and mortality. In Dessie, the prevalence of the commmon pathogens and antibiotic susceptibility pattern is not well studied sofar. Thus, the aim of this study is to address these gaps in the study area.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25280498 PMCID: PMC4195856 DOI: 10.1186/1756-0500-7-687
Source DB: PubMed Journal: BMC Res Notes ISSN: 1756-0500
Sex distribution of patients in the Dessie regional health research laboratory, May, 2012
| S. No | Patient characteristics | Frequency (%) |
|---|---|---|
|
| ||
| Not mentioned | 34 (1.4) | |
| Male | 758 (30.5) | |
| Female | 1694 (68.1) | |
| Total |
| |
|
| ||
| Not mentioned | 218 (8.8) | |
| <5 years | 62 (2.5) | |
| 5-15 | 151 (6.1) | |
| 16-35 | 1373 (55.2) | |
| 36-50 | 487 (19.6) | |
| > = 51 | 195 (7.8) | |
|
|
|
Distribution of samples in years in Dessie regional health research laboratory, May, 2012
| S. No | Year | Samples (%) |
|---|---|---|
| 1 | 2002 | 317 (12.8) |
| 2 | 2003 | 323 (13.0) |
| 3 | 2004 | 357 (14.4) |
| 4 | 2005 | 266 (10.7) |
| 5 | 2006 | 234 (9.4) |
| 6 | 2007 | 285 (11.5) |
| 7 | 2008 | 201 (8.1) |
| 8 | 2009 | 177 (7.1) |
| 9 | 2010 | 128 (5.1) |
| 10 | 2011 | 198 (8.0) |
|
|
|
|
Figure 1Distribution of isolated bacteria per year in Dessie regional laboratory, May 2012.
Figure 2Distribution of Isolated microorganisms in Dessie regional laboratory, May, 2012.
Antibiotic Susceptibility pattern of isolated microorganisms in Dessie regional health research laboratory, May, 2012
| Antibiotic |
|
|
|
|
|
|
|
|
| |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| T t | %S | T t | %S | T t | %S | T t | %S | T t | %S | T t | %S | T t | %S | T t | %S | T t | %S | |
| Amoxicillin | 182 | 28(15.4) | 8 | 1/8 | 14 | 0/14 | 3 | 1/3 | 20 | 6(30.0) | 5 | 0/5 | 5 | 1/5 | 1 | 1/1 | 1 | 0/1 |
| Tetracycline | 314 | 56(17.8) | 16 | 6(37.5) | 23 | 6(26.1) | 10 | 3/10 | 26 | 9(34.6) | 19 | 8(42.1) | 4 | 0/4 | 2 | 1/2 | 7 | 0/7 |
| TMP-SMX | 231 | 56(24.2) | 27 | 9(33.3) | 17 | 6(35.3) | 15 | 4/15 | 23 | 8(34.8) | 15 | 12/15 | 8 | 2/8 | 1 | 0/1 | 4 | ¾ |
| Cephalothin | 71 | 41(57.7) | 8 | 0/8 | 10 | 3/10 | 2 | 1/3 | 5 | 5/5 | 7 | 2/7 | 5 | 2/5 | 1 | 0/1 | 2 | ½ |
| Ampicillin | 45 | 9(20.0) | 3 | 1/3 | 4 | 0/4 | 1 | 0/1 | 8 | 1/8 | 1 | 0/1 | 1 | 0/1 | 2 | 2/2 | 1 | 0/1 |
| Chloramphenicol | 201 | 104(51.0 | 15 | 12/15 | 16 | 5(31.3) | 7 | 4/7 | 21 | 13(61.9 | 19 | 13(68.4) | 4 | 2/4 | 2 | 2/2 | 5 | 3/5 |
| Ceftriaxone | 196 | 104(53.1 | 15 | 10/15 | 14 | 614 | 14 | 8/14 | 23 | 11(47.8 | 15 | 11/15 | 2 | 2/2 | 2 | 2/2 | 3 | 2/3 |
| Ciprofloxacin | 92 | 66(71.7) | 43 | 41(95.3) | 10 | 9/1 | 18 | 11(61.1) | 10 | 6/4 | 17 | 15(88.2) | 4 | ¾ | 3 | 1/3 | 5 | 4/5 |
| Doxycyclin | 62 | 22(35.5) | 10 | 2/10 | 7 | 2/7 | 3 | 2/3 | 7 | 4/7 | 1 | 1/1 | - | - | - | - | 1 | 0/1 |
| Erythromycin | 125 | 7(5.6) | 39 | 7(17.9) | 17 | 4(23.5) | 27 | 10(37.0) | 11 | 1/11 | 14 | 3/14 | 4 | 2/4 | 2 | 2/2 | 6 | 0/6 |
| Gentamicin | 362 | 239(66.0) | 18 | 13(72.2) | 25 | 16(64.0) | 7 | 4/7 | 35 | 20(57.1) | 19 | 16(84.2) | 5 | 4/5 | 3 | 2/3 | 6 | 0/6 |
| Kanamycin | 145 | 116(80.0) | - | - | 8 | 5/8 | 1 | 0/1 | 4 | 2/4 | 1 | 0/1 | - | - | - | - | 2 | 0/2 |
| Naldixic acid | 105 | 91(86.7) | - | - | 8 | 5/8 | - | - | 9 | 9/9 | ||||||||
| Nitrofurantoin | 48 | 43(89.6) | 4 | 4/4 | 4 | 4/4 | 3 | 3/3 | 6 | 4/6 | 6 | 5/6 | - | - | 1 | 1/1 | 1 | 1/1 |
| Penicillin G | 2 | ½ | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Vancomycin | 31 | 3(9.7) | 9 | 1/9 | 3 | 0/3 | 3 | 0/3 | 1 | 0/1 | - | - | - | - | - | - | 1 | 0/1 |
| Furantoin | 142 | 124(87.3) | 1 | 0/1 | 13 | 5/13 | 1 | 1/1 | 24 | 16(66.7) | 1 | 1/1 | 4 | 4/4 | ||||
| Carbencillin | 127 | 42(33.1) | 5 | 0/5 | 14 | 5/14 | 2 | 0/2 | 3 | 0/3 | 2 | 2/2 | 3 | 1/3 | 2 | 0/2 | ||
| Clindamycin | 26 | 16(61.5) | 5 | 1/5 | 3 | 1/3 | -- | - | 1 | 0/1 | 3 | 2/3 | - | - | - | - | 2 | ½ |
| Bacitracin | 45 | 13(28.9) | - | - | 7 | 2/7 | - | - | 4 | ¼ | - | - | 1 | 0/1 | - | - | - | |
| Streptomycin | 10 | 1/10 | - | - | - | - | - | - | 5 | 2/5 | - | - | - | - | - | - | - | - |
| Oxacyclin | 12 | 12/12 | 3 | 2/3 | 1 | 0/1 | 1 | 0/1 | - | - | 4 | 4/4 | 1 | 0/1 | - | - | 1 | 0/1 |
*Cut-off levels to establish sensitivity was done based on Oxoid the FDA susceptivity test interprative criteria available at: http://www.oxoid.com.
**Abbreviations : T Total tests, %S percent of sensitive results; for those samples ≤15 total sensitive/total tests (T /T was used, TMP-SMX- trimetoprim-sulphamethoxazole, spps species.